Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis

Jay Michael S Balagtas, Gary V. Dahl

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Hereditary hemochromatosis (HH) is an autosomal-recessive disorder of iron metabolism that most commonly manifests in the fourth or fifth decade of life. Here, we describe a 14-year-old male who presented with high-risk acute lymphoblastic leukemia and previously undiagnosed HH. His treatment course was remarkable for significant therapeutic complications, including iron overload, hepatic failure, cardiac dysfunction, and death. Postmortem testing revealed homozygosity for the C282Y mutation, confirming the diagnosis of HH. Since HH mutations occur commonly in select populations, screening patients with leukemia for HH may better inform treatment decisions regarding chemotherapy, transfusions, and/or iron chelation therapy.

Original languageEnglish (US)
Pages (from-to)101-103
Number of pages3
JournalPediatric Blood and Cancer
Volume58
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Keywords

  • ALL
  • Chemotherapy
  • Hemochromatosis
  • HFE
  • Leukemia
  • Pediatric hematology/oncology

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Fingerprint Dive into the research topics of 'Therapeutic complications in a patient with high-risk acute lymphoblastic leukemia and undiagnosed hereditary hemochromatosis'. Together they form a unique fingerprint.

  • Cite this